6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Sign Up to like & getrecommendations! Published in 2019 at "The Lancet"
DOI: 10.1016/s0140-6736(19)30653-1
Abstract: BACKGROUND In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we… read more here.
Keywords: adjuvant trastuzumab; month group; months adjuvant; group ... See more keywords
6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000024995
Abstract: Abstract Background: Adjuvant trastuzumab improves survival outcomes of human epidermal receptor 2 positive early breast cancer patients. Currently, administration of 12 months adjuvant trastuzumab is the standard therapy. However, whether 6 months treatment is non-inferior to the… read more here.
Keywords: adjuvant trastuzumab; breast cancer; treatment; months adjuvant ... See more keywords
Three versus six months of adjuvant chemotherapy for colorectal cancer: A multi-country cost-effectiveness and budget impact analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.7076
Abstract: 7076Background: The international Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority and significantly less toxicity of 3 versus 6 months of adjuvant chemotherapy for patient... read more here.
Keywords: adjuvant chemotherapy; months adjuvant; six months; three versus ... See more keywords